BioSpace News Archive

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Huntington’s disease (HD) and cancer, announced the appointment of Robert Scala as Chief Commercial Officer.

Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways announced that it has dosed the first patient in the SEQUEL (Study of EEG QUantification with ELayta) Study of CT1812 (Elayta™) in adults with mild-to-moderate Alzheimer’s disease

BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its second-quarter 2020 financial results and host an operational update conference call on Thursday, September 3 rd , 2020, at 8 a.m. Eastern Time. The conference call may be accessed by dialing 1-877-451-6152 (U.S.) or 1-201-389-0879 (internati

NuGenerex Immuno-Oncology (NGIO) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August 27, 2020 at 9:30 am.

Dr. Wen’s appointment bolsters the Company’s neuro-oncology expertise in preparation for upcoming clinical trials of Berubicin in glioblastoma

Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the expansion of its product portfolio with new service packages for cell

Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces that President and CEO Michael Nall will present at the LD Micro 500 Virtual Conference on Wednesday, September 2 , at 10:40 a.m. Eas

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (“4Front” or the “Company”) today announces it plans to issue its fiscal second quarter 2020 earnings press release on Monday, August 31, 2020, after U.S. markets close, commensurate with the filing of its unaudited financial results.

Rite Aid has appointed Bari Harlam to its board of directors effective Sept. 1, 2020.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA, today announced a collaborative agreement with Mass General Cancer Center (MGCC) of Massachusetts General Hospital, related to an investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali®),